SAGE Therapeutics (NASDAQ:SAGE) Rating Lowered to Sell at BidaskClub

SAGE Therapeutics (NASDAQ:SAGE) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports.

SAGE has been the topic of a number of other research reports. William Blair restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Wedbush assumed coverage on shares of SAGE Therapeutics in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $207.00 price objective on the stock. Oppenheimer decreased their price objective on shares of SAGE Therapeutics from $200.00 to $190.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 7th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of SAGE Therapeutics in a research report on Wednesday, July 24th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $200.27.

Shares of SAGE stock traded down $0.84 during mid-day trading on Wednesday, reaching $160.06. The stock had a trading volume of 8,821 shares, compared to its average volume of 360,666. The stock’s 50-day moving average price is $164.49 and its two-hundred day moving average price is $168.11. SAGE Therapeutics has a 52-week low of $79.88 and a 52-week high of $193.56. The firm has a market capitalization of $7.84 billion, a PE ratio of -20.03 and a beta of 2.55. The company has a current ratio of 16.00, a quick ratio of 16.00 and a debt-to-equity ratio of 0.03.



SAGE Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($3.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.32) by $0.04. The firm had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $0.27 million. During the same quarter in the previous year, the firm posted ($0.36) EPS. SAGE Therapeutics’s revenue was down 99.0% compared to the same quarter last year. On average, equities research analysts forecast that SAGE Therapeutics will post -13.32 earnings per share for the current year.

In related news, Director James M. Frates sold 8,000 shares of the business’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $160.58, for a total transaction of $1,284,640.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.60% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Aperio Group LLC boosted its stake in SAGE Therapeutics by 37.0% during the second quarter. Aperio Group LLC now owns 7,515 shares of the biopharmaceutical company’s stock worth $1,376,000 after acquiring an additional 2,030 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its stake in SAGE Therapeutics by 127.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 49,944 shares of the biopharmaceutical company’s stock worth $8,233,000 after acquiring an additional 27,980 shares in the last quarter. Arden Trust Co bought a new stake in SAGE Therapeutics during the second quarter worth about $279,000. Metropolitan Life Insurance Co NY boosted its stake in SAGE Therapeutics by 5.0% during the first quarter. Metropolitan Life Insurance Co NY now owns 3,670 shares of the biopharmaceutical company’s stock worth $583,000 after acquiring an additional 174 shares in the last quarter. Finally, Xact Kapitalforvaltning AB boosted its stake in SAGE Therapeutics by 14.0% during the second quarter. Xact Kapitalforvaltning AB now owns 8,144 shares of the biopharmaceutical company’s stock worth $1,491,000 after acquiring an additional 1,000 shares in the last quarter.

About SAGE Therapeutics

Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD).

See Also: What is an economic bubble?

Analyst Recommendations for SAGE Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.